Preferred Agents During Treatment of 2nd Line RCC

Preferred Agents During Treatment of 2nd Line RCC

User Photo
obr

1 year
170 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Michael B. Atkins MD at Georgetown Lombardi Comprehensive Cancer Center, Scholl Professor and Vice Chair Department of Oncology discusses the preferred agents in the 2nd line setting of RCC once a patient has progressed on pembrolizumab/axitinib or ipilimumab/nivolumab.
Up Next Autoplay
User Photo